Talfirastide is under clinical development by Constant Therapeutics and currently in Phase II for Ischemic Stroke. According to GlobalData, Phase II drugs for Ischemic Stroke have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Talfirastide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Talfirastide overview
Talfirastide (TXA-127) is under development for the treatment of dystrophic epidermolysis bullosa (DEB), ischemic stroke, DMD-associated dilated cardiomyopathy. It is administered through oral, parenteral subcutaneous and intravenous route. It is a naturally occurring peptide Angiotensin (1-7). It is developed based on the Peptelligence platform that comprises peptide oral drug delivery for the enhanced delivery of TXA-127. It was also under development for chemotherapy induced thrombocytopenia, HIV, double cord stem cell engraftment, pulmonary arterial hypertension, peripheral vascular disease, myelodysplastic syndrome, coronavirus disease 2019 (covid-19) associated acute respiratory distress syndrome, marfan syndrome, diabetes, amyotrophic lateral sclerosis (ALS), laminin-deficient congenital muscular dystrophy (LAMA), and Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome causing coronavirus 2 (SARS-CoV-2).
Constant Therapeutics overview
Constant Therapeutics, formerly Constant Pharmaceuticals LLC, is a clinical-stage biopharmaceutical company developing peptides and small molecules for the treatment of stroke and orphan diseases. The company’s product pipeline products include TXA127 for endothelial diseases like chronic stroke. Constant Therapeutics also develops pipeline products for orphan diseases like duchenne muscular dystrophy and epidermolysis bullosa, and for fibrotic diseases. It utilizes XITRA, platform for the development of small molecule agonists targeting the Mas and MrgD receptors. Constant Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of Talfirastide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
